
## George P Tegos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4185386/publications.pdf Version: 2024-02-01



CEORCE P TECOS

#	Article	IF	CITATIONS
1	Photoantimicrobials—are we afraid of the light?. Lancet Infectious Diseases, The, 2017, 17, e49-e55.	4.6	498
2	Photodynamic therapy with fullerenes. Photochemical and Photobiological Sciences, 2007, 6, 1139-1149.	1.6	259
3	Cationic Fullerenes Are Effective and Selective Antimicrobial Photosensitizers. Chemistry and Biology, 2005, 12, 1127-1135.	6.2	231
4	Phenothiazinium Antimicrobial Photosensitizers Are Substrates of Bacterial Multidrug Resistance Pumps. Antimicrobial Agents and Chemotherapy, 2006, 50, 196-203.	1.4	172
5	Protease-Stable Polycationic Photosensitizer Conjugates between Polyethyleneimine and Chlorin(e6) for Broad-Spectrum Antimicrobial Photoinactivation. Antimicrobial Agents and Chemotherapy, 2006, 50, 1402-1410.	1.4	167
6	Inhibitors of Bacterial Multidrug Efflux Pumps Potentiate Antimicrobial Photoinactivation. Antimicrobial Agents and Chemotherapy, 2008, 52, 3202-3209.	1.4	125
7	Photodynamic therapy with a cationic functionalized fullerene rescues mice from fatal wound infections. Nanomedicine, 2010, 5, 1525-1533.	1.7	118
8	Terms of endearment: Bacteria meet graphene nanosurfaces. Biomaterials, 2016, 89, 38-55.	5.7	63
9	Light-based technologies for management of COVID-19 pandemic crisis. Journal of Photochemistry and Photobiology B: Biology, 2020, 212, 111999.	1.7	61
10	Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCC2 transporters. Analytical Biochemistry, 2013, 437, 77-87.	1.1	57
11	Attaching the NorA Efflux Pump Inhibitor INF55 to Methylene Blue Enhances Antimicrobial Photodynamic Inactivation of Methicillin-Resistant <i>Staphylococcus aureus in Vitro</i> and <i>in Vivo</i> . ACS Infectious Diseases, 2017, 3, 756-766.	1.8	44
12	Light-activated molecular machines are fast-acting broad-spectrum antibacterials that target the membrane. Science Advances, 2022, 8, .	4.7	28
13	Disruptive innovations: new anti-infectives in the age of resistance. Current Opinion in Pharmacology, 2013, 13, 673-677.	1.7	25
14	A Selective ATP-Binding Cassette Subfamily G Member 2 Efflux Inhibitor Revealed via High-Throughput Flow Cytometry. Journal of Biomolecular Screening, 2013, 18, 26-38.	2.6	20
15	A high throughput flow cytometric assay platform targeting transporter inhibition. Drug Discovery Today: Technologies, 2014, 12, e95-e103.	4.0	20
16	Dissecting novel virulent determinants in the <i>Burkholderia cepacia</i> complex. Virulence, 2012, 3, 234-237.	1.8	15
17	High-Throughput Flow Cytometry Screening of Multidrug Efflux Systems. Methods in Molecular Biology, 2018, 1700, 293-318.	0.4	12
18	Therapeutic Options and Emerging Alternatives for Multidrug Resistant Staphylococcal Infections. Current Pharmaceutical Design, 2015, 21, 2058-2072.	0.9	11

GEORGE P TEGOS

#	Article	IF	CITATIONS
19	Pneumonia and Pleural Empyema due to a Mixed Lactobacillus spp. Infection as a Possible Early Esophageal Carcinoma Signature. Frontiers in Medicine, 2016, 3, 42.	1.2	7
20	Biodefense. Virulence, 2013, 4, 740-744.	1.8	5
21	Defining the microbial effluxome in the content of the host-microbiome interaction. Frontiers in Pharmacology, 2015, 6, 31.	1.6	5
22	Editorial (Thematic Issue: Versatile Approaches to Target Staphylococcal Infections). Current Pharmaceutical Design, 2015, 21, 2046-2047.	0.9	0